Mode
Text Size
Log in / Sign up
Phase 4 Completed N=75 Randomized Double-blind Prevention

Labetalol and Esmolol: Vital Signs and Post Operative Pain Management

Source: ClinicalTrials.gov NCT01114971 ↗
Enrolled (actual)
75
Serious AEs
0.0%
Results posted
Feb 2020
Primary outcomePrimary: Postoperative Pain — 3.2; 3; 3.9 Score on scale 0-10
◆ Published Evidence
No publication linked

No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.

Summary

This study proposes to investigate the effects of labetalol or esmolol on managing the vital signs (like blood pressure and heart rate) during surgery, on pain management, and on the later recovery after surgery. It will also assess the cost-effectiveness of Labetalol and esmolol for outpatient surgery.

Outcome Measures

OutcomeResultp-value
PRIMARY
Postoperative Pain
3.2; 3; 3.9
SECONDARY
Number of Participant With Opioid Consumption
15; 14; 13
SECONDARY
Postoperative Nausea and Vomiting
9; 4; 7
SECONDARY
Return to Feeling Normal
11; 10; 12
SECONDARY
Patient Satisfaction Using a Verbal Rating Scale From 0 to 10
9.1; 9; 8
SECONDARY
Low Appetite
15; 7; 9

Eligibility Criteria

Inclusion Criteria

  • Patients scheduled to undergo outpatient surgery procedures
  • Willingness and ability to sign an informed consent document
  • No allergies to anesthetic or analgesic medications
  • 18 - 80 years of age
  • American Society of Anesthesiologists (ASA) physical status classification I - III adults of either sex
  • Women of childbearing potential must be currently practicing an acceptable form of birth control, and have a negative urine pregnancy test

Exclusion Criteria

  • Patients with known allergy, hypersensitivity or contraindications to anesthetic or analgesic medications
  • Patients with clinically-significant medical conditions, such as brain, heart, kidney, endocrine, or liver diseases, peptic ulcer disease or bleeding disorders
  • Pregnant or lactating women
  • Subjects with a history of alcohol or drug abuse within the past 3 months
  • Any other conditions or use of any medication which may interfere with the conduct of the study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01114971). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search